Pharmacyte Biotech Inc (PMCB) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: -$148.8K

PMCB ranks #7638 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PMCB is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

28 institutions disclose a position in PMCB, but none treat it as a major bet — even Citadel Advisors LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

UBS Group AG has added to its PMCB position for two straight quarters, increasing it by $1.2K to reach $3.2K today.

Hrt Financial LP has trimmed its PMCB position for two straight quarters, cutting it by $121.0K while still holding $11.0K.

PMCB reported a net loss of $16.1M over the trailing twelve months.

• Not yet profitable — net loss of $16.1M over the trailing twelve months
• Net income declined year over year, from -$1.1M to -$16.1M
• Operating cash flow was negative, using $5.2M in cash
• Current ratio of 45.28x — enough short-term assets to cover short-term liabilities
• Liabilities run 4524.38x equity — a highly leveraged balance sheet worth noting